Swedbank AB Makes New Investment in Insmed, Inc. $INSM

Swedbank AB bought a new position in Insmed, Inc. (NASDAQ:INSM) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 59,552 shares of the biopharmaceutical company’s stock, valued at approximately $10,364,000.

A number of other hedge funds have also added to or reduced their stakes in the business. CIBC Private Wealth Group LLC increased its holdings in shares of Insmed by 42.1% during the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 53 shares in the last quarter. Kingsview Wealth Management LLC increased its holdings in shares of Insmed by 2.7% during the third quarter. Kingsview Wealth Management LLC now owns 2,321 shares of the biopharmaceutical company’s stock valued at $334,000 after acquiring an additional 60 shares in the last quarter. Choreo LLC increased its holdings in shares of Insmed by 2.9% during the third quarter. Choreo LLC now owns 2,319 shares of the biopharmaceutical company’s stock valued at $334,000 after acquiring an additional 65 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of Insmed by 10.2% during the fourth quarter. EverSource Wealth Advisors LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 69 shares during the last quarter. Finally, ORG Partners LLC boosted its position in shares of Insmed by 12.7% during the fourth quarter. ORG Partners LLC now owns 657 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 74 shares during the last quarter.

Insmed Stock Up 2.5%

INSM stock opened at $108.87 on Wednesday. The stock’s fifty day simple moving average is $136.61 and its two-hundred day simple moving average is $159.60. The company has a current ratio of 4.47, a quick ratio of 4.10 and a debt-to-equity ratio of 0.80. Insmed, Inc. has a 1-year low of $65.56 and a 1-year high of $212.75. The stock has a market cap of $23.60 billion, a P/E ratio of -18.93 and a beta of 0.89.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.14. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The business had revenue of $305.96 million for the quarter, compared to analysts’ expectations of $300.81 million. During the same quarter in the previous year, the firm earned ($1.42) earnings per share. The business’s revenue was up 229.7% on a year-over-year basis. Analysts expect that Insmed, Inc. will post -2.52 EPS for the current year.

Insiders Place Their Bets

In other Insmed news, insider Michael Alexander Smith sold 19,638 shares of the business’s stock in a transaction on Monday, March 30th. The stock was sold at an average price of $150.98, for a total value of $2,964,945.24. Following the transaction, the insider owned 51,871 shares of the company’s stock, valued at approximately $7,831,483.58. The trade was a 27.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO William Lewis sold 10,699 shares of the business’s stock in a transaction on Thursday, March 19th. The stock was sold at an average price of $143.52, for a total value of $1,535,520.48. Following the completion of the transaction, the chief executive officer directly owned 301,185 shares in the company, valued at approximately $43,226,071.20. This represents a 3.43% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 156,643 shares of company stock valued at $24,513,766. Insiders own 2.10% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on INSM. Morgan Stanley raised Insmed from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $166.00 to $212.00 in a research report on Monday, March 30th. Wells Fargo & Company cut their target price on Insmed from $177.00 to $160.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Insmed in a research report on Tuesday, April 21st. Leerink Partners lifted their target price on Insmed from $210.00 to $215.00 and gave the company an “outperform” rating in a research report on Tuesday, March 24th. Finally, Royal Bank Of Canada cut their target price on Insmed from $220.00 to $205.00 and set an “outperform” rating on the stock in a research report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $210.95.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.